Fig. 6
From: Apoptosis inhibitor of macrophage (AIM)/CD5L is involved in the pathogenesis of COPD
Blood AIM/IgM ratios in humans. (A) Plasma AIM/IgM ratio in nonsmokers, healthy smokers, and smokers with COPD. (B) Serum AIM/IgM ratio in patients with COPD classified by the degree of airflow limitation (GOLD classification). The Kaplan–Meier curves for time to first exacerbation (C), all-cause mortality (D), and respiratory-cause mortality (E) among patients with COPD classified by serum AIM/IgM ratio. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005 by the Tukey–Kramer test for (A), Jonckheere–Terpsta test for (B), and log-rank trend test for (C)–(E).